Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Mar;43(2):e70049.
doi: 10.1002/hon.70049.

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Francesco Autore  1 , Daniele Mannina  2 , Federica Lessi  3 , Eugenio Galli  1 , Stefania Oliva  4 , Daniele Derudas  5 , Claudia Giannotta  2 , Claudia Crippa  6 , Katia Mancuso  7   8 , Magda Marcatti  9 , Idanna Innocenti  1 , Rita Mazza  2 , Stefania Bramanti  2 , Luca Laurenti  1   10
Affiliations
Multicenter Study

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Francesco Autore et al. Hematol Oncol. 2025 Mar.

Abstract

Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

Keywords: POEMS; VEGF; aPBSCT.

PubMed Disclaimer

References

    1. A. Dispenzieri, “POEMS Syndrome: 2021 Update on Diagnosis, Risk‐Stratification, and Management,” American Journal of Hematology 96, no. 7 (2021): 872–888, https://doi.org/10.1002/ajh.26240.
    1. O. Watanabe, K. Arimura, I. Kitajima, M. Osame, and I. Maruyama, “Greatly Raised Vascular Endothelial Growth Factor (VEGF) in POEMS Syndrome,” Lancet 347, no. 9002 (1996): 702, https://doi.org/10.1016/s0140‐6736(96)91261‐1.
    1. E. Nobile‐Orazio, F. Terenghi, C. Giannotta, F. Gallia, and A. Nozza, “Serum VEGF Levels in POEMS Syndrome and in Immune‐Mediated Neuropathies,” Neurology 72, no. 11 (2009): 1024–1026, https://doi.org/10.1212/01.wnl.0000344569.13496.ff.
    1. L. Coultas, K. Chawengsaksophak, and J. Rossant, “Endothelial Cells and VEGF in Vascular Development,” Nature 438, no. 7070 (2005): 937–945, https://doi.org/10.1038/nature04479.
    1. A. Jaccard, B. Royer, D. Bordessoule, J. C. Brouet, and J. P. Fermand, “High‐dose Therapy and Autologous Blood Stem Cell Transplantation in POEMS Syndrome,” Blood 99, no. 8 (2002): 3057–3059, https://doi.org/10.1182/blood.v99.8.3057.

LinkOut - more resources